Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Brodalumab> ?p ?o }
Showing triples 1 to 72 of
72
with 100 triples per page.
- Brodalumab abstract "Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. It is being tested for the treatment of moderate to severe psoriasis in Phase III clinical trials as of November 2013.Brodalumab was developed by Amgen, Inc.In November 2014, Amgen and AstraZeneca reported encouraging results for the compound. The companies stated that the compound met the primary endpoint showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo.However, in May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having "events of suicidal ideation and behavior". AstraZeneca will be solely responsible for any future development and marketing of brodalumab in all territories except for certain Asian territories such as Japan, where Kyowa Hakko Kirin has rights to brodalumab.".
- Brodalumab atcPrefix "none".
- Brodalumab casNumber "1174395-19-7".
- Brodalumab wikiPageID "33023911".
- Brodalumab wikiPageLength "3954".
- Brodalumab wikiPageOutDegree "12".
- Brodalumab wikiPageRevisionID "664132946".
- Brodalumab wikiPageWikiLink Amgen.
- Brodalumab wikiPageWikiLink AstraZeneca.
- Brodalumab wikiPageWikiLink Atomic_mass_unit.
- Brodalumab wikiPageWikiLink Category:Amgen.
- Brodalumab wikiPageWikiLink IL17RA.
- Brodalumab wikiPageWikiLink Interleukin-17_receptor.
- Brodalumab wikiPageWikiLink Interleukin_17.
- Brodalumab wikiPageWikiLink Interleukin_17_receptor_A.
- Brodalumab wikiPageWikiLink Ixekizumab.
- Brodalumab wikiPageWikiLink KDa.
- Brodalumab wikiPageWikiLink Kyowa_Hakko_Kirin.
- Brodalumab wikiPageWikiLink Phase_III_clinical_trial.
- Brodalumab wikiPageWikiLink Phases_of_clinical_research.
- Brodalumab wikiPageWikiLink Psoriasis.
- Brodalumab wikiPageWikiLink Ustekinumab.
- Brodalumab wikiPageWikiLinkText "Brodalumab".
- Brodalumab wikiPageWikiLinkText "brodalumab".
- Brodalumab atcPrefix "none".
- Brodalumab c "6372".
- Brodalumab casNumber "1174395".
- Brodalumab chemspiderid "NA".
- Brodalumab h "9840".
- Brodalumab hasPhotoCollection Brodalumab.
- Brodalumab kegg "D10061".
- Brodalumab legalStatus "Investigational".
- Brodalumab mabType "mab".
- Brodalumab molecularWeight "144.06".
- Brodalumab n "1712".
- Brodalumab o "1988".
- Brodalumab s "52".
- Brodalumab source "u".
- Brodalumab target IL17RA.
- Brodalumab target Interleukin_17_receptor_A.
- Brodalumab type "mab".
- Brodalumab verifiedfields "changed".
- Brodalumab verifiedrevid "459982905".
- Brodalumab watchedfields "changed".
- Brodalumab wikiPageUsesTemplate Template:Antineoplastic-drug-stub.
- Brodalumab wikiPageUsesTemplate Template:As_of.
- Brodalumab wikiPageUsesTemplate Template:Drugbox.
- Brodalumab wikiPageUsesTemplate Template:Monoclonal-antibody-stub.
- Brodalumab wikiPageUsesTemplate Template:Monoclonals_for_immune_system.
- Brodalumab subject Category:Amgen.
- Brodalumab hypernym Antibody.
- Brodalumab type Article.
- Brodalumab type ChemicalSubstance.
- Brodalumab type Company.
- Brodalumab type Drug.
- Brodalumab type Antibody.
- Brodalumab type Article.
- Brodalumab type Chemical.
- Brodalumab type Company.
- Brodalumab type Drug.
- Brodalumab type ChemicalObject.
- Brodalumab type Thing.
- Brodalumab type Q8386.
- Brodalumab comment "Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. It is being tested for the treatment of moderate to severe psoriasis in Phase III clinical trials as of November 2013.Brodalumab was developed by Amgen, Inc.In November 2014, Amgen and AstraZeneca reported encouraging results for the compound.".
- Brodalumab label "Brodalumab".
- Brodalumab sameAs برودالوماب.
- Brodalumab sameAs Brodalumab.
- Brodalumab sameAs m.0h561_2.
- Brodalumab sameAs Q4972934.
- Brodalumab sameAs Q4972934.
- Brodalumab wasDerivedFrom Brodalumab?oldid=664132946.
- Brodalumab isPrimaryTopicOf Brodalumab.